| __timestamp | Apellis Pharmaceuticals, Inc. | Iovance Biotherapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 2908166 | 9335772 |
| Thursday, January 1, 2015 | 6356782 | 12390000 |
| Friday, January 1, 2016 | 4303743 | 25602000 |
| Sunday, January 1, 2017 | 10463151 | 21262000 |
| Monday, January 1, 2018 | 22639184 | 28430000 |
| Tuesday, January 1, 2019 | 67046483 | 40849000 |
| Wednesday, January 1, 2020 | 139401000 | 60210000 |
| Friday, January 1, 2021 | 176771000 | 83664000 |
| Saturday, January 1, 2022 | 277163000 | 104097000 |
| Sunday, January 1, 2023 | 500815000 | 106916000 |
Unleashing insights
In the dynamic world of biotechnology, managing costs is crucial for sustaining growth and innovation. Apellis Pharmaceuticals, Inc. and Iovance Biotherapeutics, Inc. have demonstrated contrasting trajectories in their Selling, General, and Administrative (SG&A) expenses over the past decade.
From 2014 to 2023, Apellis Pharmaceuticals saw a staggering increase in SG&A expenses, surging by over 17,000%, reflecting their aggressive expansion and investment in operational capabilities. In contrast, Iovance Biotherapeutics experienced a more moderate rise of approximately 1,000%, indicating a more measured approach to scaling their operations.
By 2023, Apellis's SG&A expenses reached nearly five times that of Iovance, highlighting their distinct strategic priorities. This divergence underscores the varied paths companies can take in the biotech sector, balancing between rapid growth and sustainable management. Understanding these trends offers valuable insights into the financial strategies of leading biotech firms.
Breaking Down SG&A Expenses: AstraZeneca PLC vs Iovance Biotherapeutics, Inc.
Amgen Inc. vs Apellis Pharmaceuticals, Inc.: SG&A Expense Trends
SG&A Efficiency Analysis: Comparing Takeda Pharmaceutical Company Limited and Iovance Biotherapeutics, Inc.
SG&A Efficiency Analysis: Comparing Viatris Inc. and Iovance Biotherapeutics, Inc.
Operational Costs Compared: SG&A Analysis of Insmed Incorporated and Iovance Biotherapeutics, Inc.
SG&A Efficiency Analysis: Comparing Dr. Reddy's Laboratories Limited and Iovance Biotherapeutics, Inc.
Who Optimizes SG&A Costs Better? Exelixis, Inc. or Iovance Biotherapeutics, Inc.
Who Optimizes SG&A Costs Better? Amneal Pharmaceuticals, Inc. or Iovance Biotherapeutics, Inc.
Ultragenyx Pharmaceutical Inc. vs Apellis Pharmaceuticals, Inc.: SG&A Expense Trends
Breaking Down SG&A Expenses: Apellis Pharmaceuticals, Inc. vs Ligand Pharmaceuticals Incorporated
Comparing SG&A Expenses: Apellis Pharmaceuticals, Inc. vs Wave Life Sciences Ltd. Trends and Insights
Iovance Biotherapeutics, Inc. or Travere Therapeutics, Inc.: Who Manages SG&A Costs Better?